Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Current role of oxazolidinones and lipoglycopeptides in skin and soft tissue infections

Righi, Eldaa,b; Carnelutti, Alessiaa; Bassetti, Matteoa,c

Current Opinion in Infectious Diseases: April 2019 - Volume 32 - Issue 2 - p 123–129
doi: 10.1097/QCO.0000000000000529

Purpose of review An increase of skin and soft tissue infections involving Staphylococcus aureus has been reported in community and hospital settings. Methicillin resistance in S. aureus is associated with treatment failure and increased mortality. Recently, new antimicrobials with enhanced activity against methicillin-resistant Staph. aureus have been approved for the treatment of skin and soft tissue infections. Among these, novel oxazolidinones and lipoglycopeptides represent options with favorable pharmacokinetic characteristics and safety profiles.

Recent findings Newly approved compounds include tedizolid, characterized by the availability of both oral and intravenous formulation and once daily administration and dalbavancin, a long-acting antimicrobial allowing for weekly administration. These new molecules present advantages, such as enhanced activity against multidrug-resistant Gram-positive bacteria and favorable safety profiles.

Summary We have reviewed the pharmacokinetic characteristics and the implications for use in skin and soft tissue infections of tedizolid and dalbavancin. Advantages associated with the use of these compounds include the possibility for early patient discharge, reduced hospital length of stay, and outpatient treatment, with potential impact on morbidity, mortality, and overall health-care costs.

aInfectious Diseases Clinic, Azienda Sanitaria Universitaria Integrata, Udine

bDepartment of Diagnostics and Public Health, University of Verona, Verona

cDepartment of Medicine, University of Udine, Udine, Italy

Correspondence to Elda Righi, Infectious Diseases Clinic, Azienda Sanitaria Universitaria Integrata, Piazzale Misericordia 15, 33100 Udine, Italy. Tel: +39 0432 559354; fax: +39 0432 559360; e-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.